New products and pharmacologic developments

DERMA E INTRODUCES SCALP RELIEF HAIR CARE

derma e® launched a new Scalp Relief Shampoo and Conditioner to help address symptoms of dandruff. derma e® Scalp Relief Shampoo and Scalp Relief Conditioner work in four therapeutic ways to effectively target scalp problems. The shampoo is designed to cleanse, de-flake, soothe, and nourish. The conditioner is designed to detangle, de-flake, soothe, and nourish. Both formulas contain the derma e® proprietary Therapeutic Psorzema® Herbal Blend. Neem, Burdock, and Bearberry soothe the scalp and promote optimal hair health. Tea Tree and Menthol calm and cool itch on contact. Salicylic Acid penetrates to lift away excess flakes and surface buildup, helping maintain scalp purity over time. Both formulas are consumer tested, clinically tested, allergy tested, coal tar-free, pine tar-free, steroid-free, prescription-free, and safe for color-treated hair. dermae.com

AMBI LAUNCHES EVEN & CLEAR CC+ CREAM EVEN TONE ENVIRONMENAL SHIELD

AMBI Even & Clear CC+ Cream Even Tone Environmental Shield, the first color product in the AMBI® Skincare Line, will be introduced in March. Formulated to match the rich tones of women of color, CC+ Cream contains argan oil, shea butter, and antioxidants to moisturize the skin. AMBI CC+ Cream provides broadspectrum SPF 30 protection and is formulated not to leave the skin looking ashy or gray. Available in Light/Medium and Medium/Dark, AMBI CC+ Cream is designed to even skin tone instantly with soft focus technology, while helping protect skin from environmental elements that may cause uneven skin tone, dry out the skin, and accelerate fine lines and wrinkles. shopambi.com

NEW HAIR CARE PRODUCTS FROM GLYTONE

Glytone introduced Glytone by Ducray Sensinol Physioprotective Calming Shampoo and Sensinol Physioprotective Soothing Serum to help calm irritation and itching for sensitive scalps. The Calming Shampoo soothes sensitive, itchy scalps prone to itching and severe dryness with polidocanol 2%. The shampoo is formulated with a hypoallergenic cleansing base. A clinical study with 45 subjects with sensitive scalp scale of two to five (sensitive to very sensitive) showed that 75 percent of participants experienced less itching after one week of treatment with results lasting up to two weeks following treatment with the shampoo. The Soothing Serum is a leave-in formula that contains polidocanol 2% for antipruritic action, glycine 3%, which has soothing benefits, and zinc gluconate 1% to soothe and repair the scalp's protective hydrolipidic film. Available now and exclusive to physicians, these products are free of fragrance, parabens, coloants, and alcohol. Glytone-usa.com

SPA SONIC RE-INTRODUCES SPA SONIC PRO SKIN CARE SYSTEM

Spa Sonic is re-introducing its Spa Sonic Pro Skin Care System in a new black design. With four brush head attachments, the Spa Sonic Pro serves as an all–in-one system: a small brush for the face, a large brush for the body, a pumice pad for rough areas, and a facial sponge for microdermabrasion and reduction of fine lines. After each use, skin is deeply cleansed, and pores are tighter and minimized on both the face and body. Requiring only AA-batteries, this system is lightweight and portable. The Spa Sonic Pro Skin Care System in black will be available beginning April 2015. myspasonic.com

Therapeutics Focus: Pediatric Dermatology

ASSESSING ASSOCIATION OF CENTRAL OBESITY AND HIGH BLOOD PRESSURE IN PEDIATRIC PATIENTS WITH AD

Atopic dermatitis (AD) is associated with multiple potential risk factors for obesity and high blood pressure (BP). To determine whether central obesity and high BP are increased in pediatric AD, researchers performed a case-control study in multicenter pediatric dermatology practices in the United States with 132 children between the ages of four and 17 with active moderate to severe AD and 143 healthy controls from April 1, 2009, through December 31, 2012. Body mass index, waist circumference, waist to height ratio, systolic BP, and diastolic BP were assessed. Results found that moderate to severe AD was associated with body mass index for age and sex of 97th percentile or greater, waist circumference in the 85th percentile or greater, and waist to height ratio of 0.5 or greater. Atopic dermatitis was found to be associated with higher BP for age, sex, and height percentiles, particularly a systolic BP in the 90th percentile or higher, in multivariate models that controlled for demographics, body mass index, and waist circumference percentiles, and history of using prednisone or cyclosporine. Atopic dermatitis was associated with higher systolic BP in Hispanics/Latinos and Asians. Severe to very severe AD was associated with systolic BP in the 90th percentile or higher. Atopic dermatitis was associated with a family history of hypertension and type 2 diabetes mellitus but not obesity or hyperlipidemia. Moderate to severe pediatric AD may be associated with central obesity and increased systolic BP.

—JAMA Dermatol. 2015; 151(2): 144-152

GRAPPLING WITH PREADOLESCENT DERMATOLOGICAL CONDITIONS

At the recent Maui Derm 2015 conference, Albert C. Yan, MD, Chief of the Section of Pediatric Dermatology at the Children's Hospital of Philadelphia, sat down with Joel L. Cohen, MD, to discuss the best treatment regimens for pediatric patients with acne and hair disorders. Dr. Yan shared his experience working with young patients and their families.

“Fortunately for preadolescent acne, it's a condition that is mostly comedonal—it's that typical t-zone distribution that we commonly see along the forehead and the central face and it usually responds quite well to off-label use of benzoyl peroxides and topical retinoids. Now in my practice, a lot of the kids come in already having tried things when they're motivated to treat,” said Dr. Yan, who further explained that these patients have also likely tried several over-the-counter products and are looking for something additional to help.

For more, visithttp://dermtube.com/series/daily-coverage-maui-derm-2015/ekovadog/ for more.

RETROSPECTIVE REVIEW OF RELAPSE AFTER SYSTEMIC CYCLOSPORINE FOR AD

Cycolosporine is traditionally recommended at a dose of 5mg/kg/day for six months to control severe atopic dermatitis (AD) in children, but there are few data on the short- and long-term effectiveness of longer courses of therapy. Results of a recent study suggest that a longer duration of low-dose cyclosporine may help decrease the risk of relapse in patients with severe AD who are resistant to topical therapies. A retrospective chart review of children treated with cyclosporine at a Canadian hospital-affiliated clinic between 2000 and 2013 identified 15 patients with adequate follow-up. Twelve were male and the mean age at initiation of cyclosporine was 11.2 ± 3.4 years. The mean duration of cyclosporine therapy was 10.9 ± 2.7 months (range seven–15 months) at a starting dose of 2.8 ± 0.6 mg/kg/day. Of 12 patients who responded to cyclosporine, five had relapsed at a follow-up of 22.7 ± 15.0 months. The duration of therapy was longer in patients who did not relapse (17.7 ± 10.7 months) than in those who did (10.2 ± 2.7 months). Adverse events led to discontinuation in three patients.

—Pediatric Dermatology. 2015; 32(1): 36–40